Allergopharma Joachim Ganzer KG

Allergopharma is the world leader in high dose hypoallergenic vaccines for specific immunotherapy (SIT) of Type 1 allergy, and is represented in major markets in Europe and Asia by subsidiaries or partners.

Allergopharma has become the leading company in developing new allergy vaccines, based on recombinant produced allergens as active substances. The pipeline includes vaccines comprised of recombinant molecules for grass, birch and mite allergies, representing more than 15 individual allergenic molecules.